Beam Therapeutics (BEAM) Capital Leases (2019 - 2023)

Beam Therapeutics (BEAM) has 5 years of Capital Leases data on file, last reported at $304000.0 in Q3 2023.

• Capital Leases for Q3 2023 came in at $304000.0, down 78.1% year-over-year; the trailing twelve-month figure through Sep 2023 was $304000.0 (down 78.1% YoY), and the FY2022 annual result was $1.2 million, down 61.62% from the prior year.
• Capital Leases declined to $304000.0 in Q3 2023 per BEAM's latest filing, from $875000.0 in the prior quarter.
• Over five years, Capital Leases peaked at $5.3 million in Q1 2020 and troughed at $304000.0 in Q3 2023.
• A 5-year average of $3.0 million and a median of $3.3 million in 2021 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2020 and 2023: Capital Leases advanced 20.02% in 2020, then plunged 78.1% in 2023.
• A 5-year view of Capital Leases shows it stood at $4.4 million in 2019, then grew by 20.02% to $5.3 million in 2020, then tumbled by 43.2% to $3.0 million in 2021, then slumped by 61.62% to $1.2 million in 2022, then plunged by 73.66% to $304000.0 in 2023.
• Business Quant data shows BEAM's Capital Leases at $304000.0 in Q3 2023, $875000.0 in Q2 2023, and $983000.0 in Q1 2023.